Piscataway, NJ, United States
Piscataway, NJ, United States

Time filter

Source Type

News Article | June 1, 2017
Site: globenewswire.com

Applied Research Associates, Inc. (ARA), an employee-owned scientific research and engineering company, has today announced the acquisition of Berrie Hill Research Corporation (BRC), a leading provider of Electromagnetic Modeling/Simulation, Design, Analysis and Fabrication for the Air Force and Intelligence Agencies. ARA and BRC share a common mission to provide innovative defense solutions while providing an excellent work environment for employees. With the integration of BRC’s leading-edge capabilities, ARA is poised to offer critical advancements within the fast-growing non-lethal market. “Bringing BRC technologies into ARA opens the door to many new opportunities for the combined organization. ARA customers that have needs for advanced electromagnetic based technologies will now have access through ARA. In addition, ARA gains access to BRC’s deep expertise associated with special programs,” says Dr. Frank A. Maestas, ARA’s Executive Vice President. “Both organizations are expert integrators of high-technology physics and engineering into compelling software/hardware applications and share a common culture of responsiveness and excellence. This is definitely a win-win for both companies.” Dr. Jeff Berrie, BRC President and CEO, says of the transition, “After two years of successful partnering with ARA, we realized our mutual corporate goals could be significantly accelerated by bringing BRC into ARA. ARA has a company culture that matches ours extremely well, providing outstanding service to customers and an excellent work environment for employees. Our technical areas of expertise are very complementary, and we are looking forward to a successful future as a new Division in ARA.” ARA was founded 1979 to solve problems of national importance. The company’s applied research delivers scientific solutions for national defense, homeland security, aerospace, healthcare, transportation, and manufacturing. With over 1,000 Employee Owners at locations in the U.S. and Canada, ARA offers a broad range of technical expertise in defense technologies, computer software and simulation, systems analysis, civil engineering, biomedical engineering, environmental technologies, and blast testing and measurement. For more information, visit http://www.ara.com. Founded in 2005, BRC is a small business with expertise in the design and development of antennas, computational electromagnetics, and RF measurements. BRC’s technical staff consists of engineers, scientists, and technicians with advanced degrees in engineering, applied mathematics, physics, and computer science. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/fcb42531-ca94-43a4-a4c4-e562d485d194


News Article | May 30, 2017
Site: www.eurekalert.org

Namiko Yamamoto, assistant professor of aerospace engineering at Penn State, was recently awarded $447,663 through the Office of Naval Research (ONR) Sea-Based Aviation Airframe Structures and Materials program to study fundamental toughening mechanisms of novel ceramic composites and their use as alternative materials for high-temperature applications in the aerospace industry. Through her project titled "Multi-functional Nano-porous Ceramics," Yamamoto, in collaboration with Jogender Singh, professor in the Department of Materials Science and Engineering and chief scientist in Penn State's Applied Research Laboratory, will seek to understand how the introduction of nano-pores into ceramics contributes to enhanced fracture toughness and increased damage tolerance, with minimal compromising of the material's strength. "Tougher ceramic materials are in high demand for numerous aerospace applications that require adequate mechanical strength, stability in extreme environments and lightweight materials," said Yamamoto. "Although ceramics exist that meet those requirements, their applications as bulk structural materials are currently limited to their brittleness and low fracture toughness." Ceramics have a unique combination of material properties, such as low density, high strength at high temperatures, wear resistance, corrosion resistance and low thermal and electrical conductivities. However, when high stress is placed on them, premature or catastrophic failure can occur. Recently, some unique deformation behaviors have been observed when nano-porous ceramics are indented, including shear banding of collapsed pores. If controlled, this quasi-plastic deformation could potentially contribute to intrinsic toughening of ceramics and effectively mitigate crack initiation and propagation. "Systematic understanding is currently missing about shear banding and its relation to fracture toughness of nano-porous ceramics," said Yamamoto. "By conducting multi-scale parametric studies, we hope to gain the knowledge that is critical to the acceleration of practical fabrication and use of macro-scale, nano-porous ceramic materials with increased damage tolerance. Also, through field-assisted sintering technology, we will pursue scalable manufacturing of such nano-porous ceramics." If successful, the toughened nano-porous ceramics could find use as alternative materials for high-temperature and high-shear loading applications in aerospace engineering parts, helicopter rotor heads, ball-point bearings, gear boxes, thermal and physical protection layers, abrasive cutting tools and more. Funding for the project will span three years and will support ONR's interest in the field of Sea-Based Aviation Airframe Structures and Materials. Yamamoto also received an ONR grant in 2016 for her research proposal titled "1D-Patterned Nanocomposites Structured Using Oscillating Magnetic Fields."


News Article | July 11, 2017
Site: www.prnewswire.com

NEW YORK, July 11, 2017 /PRNewswire/ -- This report analyzes the worldwide markets for Laboratory Balances and Scales in US$ Thousand by the following End-Use Sectors: Food Laboratories, Chemical Laboratories, Academia Laboratories, Pharma & Biotech Laboratories, and Other Research Laboratories. The report provides separate comprehensive analytics for the US, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Read the full report: http://www.reportlinker.com/p04707092/Global-Laboratory-Balances-and-Scales-Laboratory-Equipment-and-Supplies.html Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 30 companies including many key and niche players such as: - A&D Company Ltd. - Adam Equipment Co. Ltd. - Avery Weigh-Tronix, LLC - Bonso Electronics International, Inc. - CAS - USA Corp. Read the full report: http://www.reportlinker.com/p04707092/Global-Laboratory-Balances-and-Scales-Laboratory-Equipment-and-Supplies.html I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations Disclaimers Data Interpretation & Reporting Level Quantitative Techniques & Analytics Product Definitions and Scope of Study II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Balances and Scales: Essential Equipment for Accurate & Reliable Lab Operations Slow Yet Stable Economic Outlook Bodes Well for Laboratory Balances Market Table 1: World Real GDP Growth in % by Country/ Region for 2015-2017P (includes corresponding Graph/Chart) Pharmaceutical Industry: The Largest End-User of Lab Balances & Scales Table 2: Growth (%) of Major Pharmaceutical Markets for the Years 2014 & 2015 (includes corresponding Graph/Chart) Increased Spending in Pharmaceutical R&D Sector - Opportunity for Lab Balances & Scales Market Table 3: Pharmaceutical R&D Spending Worldwide in US$ Billion for the Years 2010, 2012, 2014, 2016, 2018 & 2020 (includes corresponding Graph/Chart) Analytical Balance - A Vital Cog in Pharmaceutical Lab Operations Pharmaceutical Compounding - High Significance of Precision Lab Balances Revised Weighing Guidelines Aim at Reducing Unwarranted Testing Increased Funding Support for Academia R&D Activities to Foster Demand for Laboratory Balances and Scales Table 4: US R&D Funding Mix (2016E) - Percentage Breakdown of R&D Spending by Academia, Federal Government, Industry and Non-Profit Organizations (includes corresponding Graph/Chart) Table 5: US R&D Funding in Academia Sector (2016E) - Proportion (%) of Academia Sector in R&D Funding for Basic Research, Applied Research, Development and Total R&D (includes corresponding Graph/Chart) Food Industry: Rising Significance of Lab Balances for Regulatory Compliance & Food Safety High Significance of Lab Balances & Scales in Food Safety Testing Forensic Laboratories - An Emerging & Promising Application Market for Lab Balances Reliability, Durability & Precision - Key Factors Considered in Purchasing Decisions of Customers Table 6: Key Factors Considered while Purchasing Laboratory Balances and Scales - Breakdown of % of Customers Considering the Factor/Feature in their Purchase Decisions (includes corresponding Graph/Chart) Table 7: Factors Contributing to Purchase of Laboratory Balance and Scale - Percentage Breakdown of Number of Customers by Reason for Purchase (includes corresponding Graph/Chart) Growing Demand for New & Improved Models: Opportunity for Market Players Technological Advancements Causing Surge in Replacement Demand Streamlined Data Collection and Data Transfer Features to Sustain Future Demand Calibration: An Often Overlooked but Vital Necessity Need for Calibration Regular Maintenance & Calibration: Keys to an Effective Lab Balance Competitive Landscape Table 8: Leading Players in the Global Laboratory Balances Market (2015): Percentage Breakdown of Revenues for Mettler-Toledo, Sartorius and Others (includes corresponding Graph/Chart) 2. PRODUCT OVERVIEW Balance The Balancing Act Precision of Balances Scale Types of Laboratory Balances and Scales Analytical Balance Beam Arrest Pan Leveling Feet Reference Position Draft Shield Factors Influencing Accuracy of Analytical Balance Temperature Vibrations Chemical Reactions Air Currents Calibration User Error Equal Arm Balance/Trip Balance Platform Scale Spring Balance Top-Loading Balance Torsion Balance Micro Balance Triple-Beam Balance Pendulum Balance Scale Hybrid Spring and Balance Scales Measurement Errors in Lab Balances & Scales End-Use Markets for Laboratory Balances & Scales - An Overview Food Laboratories Types of Food Laboratories Chemical Laboratories Academia Laboratories Pharmaceutical & Biotech Laboratories Other Laboratories 3. RECENT INDUSTRY ACTIVITY Shimadzu Launches Nine New Models in AP-W, AP-X and AP-Z Series Precisa Launches Series 390 in Asia-Pacific and China METTLER TOLEDO Launches New XPR Balance Line Adam Equipment Rolls Out Eclipse Series of Analytical and Precision Balances BEL Engineering Unveils HPB Series of Analytical Balances METTLER TOLEDO Introduces New Excellence XPE206DR Analytical Balance METTLER TOLEDO Rolls Out ME-T, Entry level Balance Model METTLER TOLEDO Unveils Precision ML-T Compact Balances METTLER TOLEDO Launches MS-TS Analytical Balances OHAUS Introduces Explorer Semi-Micro Balances RADWAG Launches 4Y Series of Laboratory Balances Adam Equipment Rolls Out Nimbus Balances in Australia and South Africa Adam Equipment Unveils Nimbus Balances in North and Latin America Adam Equipment Introduces Nimbus Balances in Europe Mettler Toledo Rolls Out XS Balance Line Mettler Toledo Rolls Out XPE Balance Line Sartorius AG Launches Entris Precision and Analytical Balance RADWAG Launches 3Y Microbalance Mettler Toledo Rolls Out Excellence Analytical Balance Line Stable Micro Systems Launches Dynamic Integrated Balance Sartorius Launches Quintix® Laboratory Balance 4. FOCUS ON SELECT PLAYERS A&D Company Ltd (Japan) Adam Equipment Co. Ltd (UK) Avery Weigh-Tronix, LLC (UK) Bonso Electronics International, Inc. (China) CAS - USA Corp (US) Contech Instruments Ltd (India) Gram Precision S.L (Spain) Kern & Sohn GmbH (Germany) Mettler Toledo International, Inc. (US) OHAUS Corporation (US) Panomex, Inc. (India) RADWAG Balances and Scales (Poland) Sartorius AG (Germany) Scientech, Inc. (US) Setra Systems Inc. (US) Shimadzu UK Limited (UK) 5. GLOBAL MARKET PERSPECTIVE Table 9: World Recent Past, Current & Future Analysis for Laboratory Balances and Scales by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 10: World Historic Review for Laboratory Balances and Scales by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 11: World 14-Year Perspective for Laboratory Balances and Scales by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) Table 12: World Recent Past, Current & Future Analysis for Laboratory Balances and Scales Use in Food Sector by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 13: World Historic Review for Laboratory Balances and Scales Use in Food Sector by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 14: World 14-Year Perspective for Laboratory Balances and Scales Use in Food Sector by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) Table 15: World Recent Past, Current & Future Analysis for Laboratory Balances and Scales Use in Chemical Sector by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 16: World Historic Review for Laboratory Balances and Scales Use in Chemical Sector by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 17: World 14-Year Perspective for Laboratory Balances and Scales Use in Chemical Sector by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) Table 18: World Recent Past, Current & Future Analysis for Laboratory Balances and Scales Use in Academia Sector by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 19: World Historic Review for Laboratory Balances and Scales Use in Academia Sector by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 20: World 14-Year Perspective for Laboratory Balances and Scales Use in Academia Sector by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) Table 21: World Recent Past, Current & Future Analysis for Laboratory Balances and Scales Use in Pharma & Biotech Sector by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 22: World Historic Review for Laboratory Balances and Scales Use in Pharma & Biotech Sector by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 23: World 14-Year Perspective for Laboratory Balances and Scales Use in Pharma & Biotech Sector by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) Table 24: World Recent Past, Current & Future Analysis for Laboratory Balances and Scales Use in Other End-Use Sectors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 25: World Historic Review for Laboratory Balances and Scales Use in Other End-Use Sectors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 26: World 14-Year Perspective for Laboratory Balances and Scales Use in Other End-Use Sectors by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III. MARKET 1. THE UNITED STATES A.Market Analysis Current and Future Analysis Product Launches Key Players B.Market Analytics Table 27: The US Recent Past, Current & Future Analysis for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 28: The US Historic Review for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 29: The US 14-Year Perspective for Laboratory Balances and Scales by End-Use Sector - Percentage Breakdown of Dollar Sales for Food, Chemicals, Academia, Pharma & Biotech and Others Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) 2. CANADA Market Analysis Table 30: Canadian Recent Past, Current & Future Analysis for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 31: Canadian Historic Review for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 32: Canadian 14-Year Perspective for Laboratory Balances and Scales by End-Use Sector - Percentage Breakdown of Dollar Sales for Food, Chemicals, Academia, Pharma & Biotech and Others Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) 3. JAPAN A.Market Analysis Current and Future Analysis Product Launch A&D Company Ltd - A Key Player B.Market Analytics Table 33: Japanese Recent Past, Current & Future Analysis for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 34: Japanese Historic Review for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 35: Japanese 14-Year Perspective for Laboratory Balances and Scales by End-Use Sector - Percentage Breakdown of Dollar Sales for Food, Chemicals, Academia, Pharma & Biotech and Others Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) 4. EUROPE Market Analysis Table 36: European Recent Past, Current & Future Analysis for Laboratory Balances and Scales by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 37: European Historic Review for Laboratory Balances and Scales by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 38: European 14-Year Perspective for Laboratory Balances and Scales by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) Table 39: European Recent Past, Current & Future Analysis for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 40: European Historic Review for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 41: European 14-Year Perspective for Laboratory Balances and Scales by End-Use Sector - Percentage Breakdown of Dollar Sales for Food, Chemicals, Academia, Pharma & Biotech and Others Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) 4a. FRANCE Market Analysis Table 42: French Recent Past, Current & Future Analysis for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 43: French Historic Review for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 44: French 14-Year Perspective for Laboratory Balances and Scales by End-Use Sector - Percentage Breakdown of Dollar Sales for Food, Chemicals, Academia, Pharma & Biotech and Others Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) 4b. GERMANY A.Market Analysis Current and Future Analysis Strategic Corporate Developments Key Players B.Market Analytics Table 45: German Recent Past, Current & Future Analysis for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 46: German Historic Review for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 47: German 14-Year Perspective for Laboratory Balances and Scales by End-Use Sector - Percentage Breakdown of Dollar Sales for Food, Chemicals, Academia, Pharma & Biotech and Others Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) 4c. ITALY A.Market Analysis Current and Future Analysis Product Launch B.Market Analytics Table 48: Italian Recent Past, Current & Future Analysis for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 49: Italian Historic Review for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 50: Italian 14-Year Perspective for Laboratory Balances and Scales by End-Use Sector - Percentage Breakdown of Dollar Sales for Food, Chemicals, Academia, Pharma & Biotech and Others Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) 4d. THE UNITED KINGDOM A.Market Analysis Current and Future Analysis Product Launches Key Players B.Market Analytics Table 51: UK Recent Past, Current & Future Analysis for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 52: UK Historic Review for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 53: UK 14-Year Perspective for Laboratory Balances and Scales by End-Use Sector - Percentage Breakdown of Dollar Sales for Food, Chemicals, Academia, Pharma & Biotech and Others Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) 4e. SPAIN A.Market Analysis Current and Future Analysis Gram Precision S.L (Spain) - A Key Player B.Market Analytics Table 54: Spanish Recent Past, Current & Future Analysis for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 55: Spanish Historic Review for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 56: Spanish 14-Year Perspective for Laboratory Balances and Scales by End-Use Sector - Percentage Breakdown of Dollar Sales for Food, Chemicals, Academia, Pharma & Biotech and Others Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) 4f. RUSSIA Market Analysis Table 57: Russian Recent Past, Current & Future Analysis for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 58: Russian Historic Review for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 59: Russian 14-Year Perspective for Laboratory Balances and Scales by End-Use Sector - Percentage Breakdown of Dollar Sales for Food, Chemicals, Academia, Pharma & Biotech and Others Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) 4g. REST OF EUROPE A.Market Analysis Current and Future Analysis Product Launches RADWAG Balances and Scales (Poland) - A Key Player B.Market Analytics Table 60: Rest of Europe Recent Past, Current & Future Analysis for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 61: Rest of Europe Historic Review for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 62: Rest of Europe 14-Year Perspective for Laboratory Balances and Scales by End-Use Sector - Percentage Breakdown of Dollar Sales for Food, Chemicals, Academia, Pharma & Biotech and Others Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) 5. ASIA-PACIFIC Market Analysis Table 63: Asia-Pacific Recent Past, Current & Future Analysis for Laboratory Balances and Scales by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 64: Asia-Pacific Historic Review for Laboratory Balances and Scales by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 65: Asia-Pacific 14-Year Perspective for Laboratory Balances and Scales by Geographic Region - Percentage Breakdown of Dollar Sales for China and Rest of Asia-Pacific Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) Table 66: Asia-Pacific Recent Past, Current & Future Analysis for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 67: Asia-Pacific Historic Review for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 68: Asia-Pacific 14-Year Perspective for Laboratory Balances and Scales by End-Use Sector - Percentage Breakdown of Dollar Sales for Food, Chemicals, Academia, Pharma & Biotech and Others Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) 5a. CHINA A.Market Analysis Current and Future Analysis Product Launch Bonso Electronics International Inc - A Key Player B.Market Analytics Table 69: Chinese Recent Past, Current & Future Analysis for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 70: Chinese Historic Review for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 71: Chinese 14-Year Perspective for Laboratory Balances and Scales by End-Use Sector - Percentage Breakdown of Dollar Sales for Food, Chemicals, Academia, Pharma & Biotech and Others Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) 5b. REST OF ASIA-PACIFIC A.Market Analysis Current and Future Analysis Key Players B.Market Analytics Table 72: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 73: Rest of Asia-Pacific Historic Review for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 74: Rest of Asia-Pacific 14-Year Perspective for Laboratory Balances and Scales by End-Use Sector - Percentage Breakdown of Dollar Sales for Food, Chemicals, Academia, Pharma & Biotech and Others Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) 6. LATIN AMERICA Market Analysis Table 75: Latin American Recent Past, Current & Future Analysis for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 76: Latin American Historic Review for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 77: Latin American 14-Year Perspective for Laboratory Balances and Scales by End-Use Sector - Percentage Breakdown of Dollar Sales for Food, Chemicals, Academia, Pharma & Biotech and Others Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) 7. REST OF WORLD Market Analysis Table 78: Rest of World Recent Past, Current & Future Analysis for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 79: Rest of World Historic Review for Laboratory Balances and Scales by End-Use Sector - Food, Chemicals, Academia, Pharma & Biotech and Others Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 80: Rest of World 14-Year Perspective for Laboratory Balances and Scales by End-Use Sector - Percentage Breakdown of Dollar Sales for Food, Chemicals, Academia, Pharma & Biotech and Others Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 30 (including Divisions/Subsidiaries - 41) The United States (19) Japan (2) Europe (11) - France (1) - Germany (2) - The United Kingdom (4) - Italy (1) - Spain (1) - Rest of Europe (2) Asia-Pacific (Excluding Japan) (8) Latin America (1) Read the full report: http://www.reportlinker.com/p04707092/Global-Laboratory-Balances-and-Scales-Laboratory-Equipment-and-Supplies.html About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. http://www.reportlinker.com __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


-- Global Terahertz Components and Systems Market Report, published by Variant Market Research, forecast that the global market is expected to reach $433.6 million by 2024 from $64.8 million in 2016, growing at a CAGR of 26.8% from 2016 to 2024. By geography, Asia Pacific and RoW are expected to grow at a CAGR of 30.2% and 27.3%, respectively, during the forecast period.The global  terahertz components and systems market (https://www.variantmarketresearch.com/report-categories/information-and-communication-technology-ict/terahertz-components-and-systems-market) is driven by the factors such as increasing use of terahertz in medical imaging and non-destructive testing, and high adoption of terahertz technology across various industrial sectors. Rising use of this technology in laboratories also fuels the growth of the market. Additionally, technologies with low-priced small radiation devices and detectors would provide market opportunities. However, inability of this technology to emphasis on spot sizes below 100 micrometers, and limitation in penetration depth into materials might hinder the adoption of terahertz components and systems.The global Terahertz Components and Systems market is categorized by component, system, applications, and geography. By component type, the market is segmented into terahertz sources, terahertz detectors, and others. Terahertz sources accounted for the largest market share in 2016, followed by terahertz detectors. Systems are categorized as spectroscopy (time-domain spectroscopy, frequency domain spectroscopy and imaging by scanning), terahertz radar and terahertz sensing. By systems, spectroscopy accounted for highest share in 2016, followed by terahertz sensing. Furthermore, applications are segmented into industrial process monitoring, research laboratory application, medical imaging, nondestructive testing, and others.By geography the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW). Asia-Pacific is expected to attain the fastest CAGR during the forecast period, owing to advancements in technology and usage of terahertz technology for medical imaging. North America accounts for the largest share of the market followed by Europe in 2016.The key players of terahertz component and systems market include M Squared Lasers Ltd, EMCORE Corporation, NEC Corporation, Microtech Instruments Inc., Bridge12 Technologies, Inc., Digital Barriers PLC, Digital Barriers Plc., Applied Research & Photonics Inc., Bruker Corporation and Menlo Systems GmbH.Variant Market Research LLP was delineated in 2015 and to launch our business and website it grabbed more than a year. Our head office is based in Pune and we also have branch in San Francisco, California, the U.S. The long time was generally used to build up a talented team of experienced professionals and analysts, to generate client satisfying exact market analysis data. The company aims to be a specialist in delivering reports on various domains with precise analysis, keeping a virtuous relationship with our consumers. Our vision says, "We would like to grow with you, making your paths simpler yet solidest" and our mission is to "Implementing our analytical, technical and marketing skills to set a new goal for our consumers, dedicatedly helping them take their next strategic moves."The Co-founders of Variant Market Research:andare keen to provide services across aforementioned domains helping them to take their strategic moves regarding their business and providing them the growth opportunities. The Co-founders say, "We believe in providing the future solutions for your business, exploring the current market trends and suggesting you the future strategies and forecast of a particular market that could keep your company ahead in the competitive market rivalry." We hold expertise in our designated areas of research and consulting with a team of experts from each of the dedicated areas covered under our research. Destined by the dedicated team of analysts and experts, we are envisioned to provide you our best in order to plan your next strategic move and take your company's future ahead with our support and your esteemed cooperation.VARIANT MARKET RESEARCH LLPhttps://www.variantmarketresearch.com/Address:649 Mission St.,5th Floor, San Francisco, CA 94105, United States.Tel: +1-415-680-2785Fax: +1-415-680-2786(mailto:help@variantmarketresearch.com)


VANCOUVER, BC--(Marketwired - February 24, 2017) - Traditional methods for reforestation use seeds from local tree populations. With the climate quickly changing, these local trees will be poorly adapted to new environments that not only have warmer temperatures, but also more disease pressures. And climate change isn't just bad for trees. It's also bad for the economic and environmental benefits they provide to Canada -- benefits like wood, jobs, habitat protection and carbon sequestration. Foresters have three options for dealing with this problem: reforest with the same species, but with trees that are better adapted to warmer climates; move species further north or to higher elevations; or select and breed trees that can better withstand climatic stresses or disease. All of these strategies can be successful, but only if we have scientific knowledge about which trees can better withstand a changing climate and the stresses that accompany it. Dr. Sally Aitken of the University of British Columbia (UBC) is leading a team, including Sam Yeaman of the University of Calgary and Richard Hamelin of UBC and Université Laval, that will use genomics to test the ability of trees from different populations to resist heat, cold, drought and disease, and identify the genes and genetic variation involved in climate adaptation. The ultimate goal of the project, valued at $5.8 million, is to develop better reforestation strategies for economically important tree species such as Douglas-fir and lodgepole pine, as well as western larch and jack pine. "Better matching trees with new climates will improve the health and productivity of planted forests. To understand the adaptation of trees to both climate and diseases, we will use genomic tools along with climate modeling and seedling experiments," says Dr. Aitken, a Professor in the Faculty of Forestry. "Our previous research has shown these approaches will give us these answers in a few years rather than in a few decades. The success of this research is dependent on our close collaboration with provincial tree breeders and forest managers." "Our ministry is pleased to be a major partner in the CoAdapTree research project, in collaboration with Dr. Aitken's team at UBC," said Forests, Lands and Natural Resource Operations Minister Steve Thomson. "Together, we are developing important tools to implement climate-based seed transfer. The B.C. government is committed to using the results of this research to improve forest management practices that will benefit all British Columbians." The project, CoAdapTree: Healthy trees for future climates, will provide recommendations for climate-based seed transfer policy to guide foresters in planting trees that will be healthy in new climates in western Canada. Climate-based seed transfer can result in up to 30% greater timber yields, with a proportional impact on the economy and employment, and will also sustain ecological and environmental benefits of forests. "The forestry industry contributed more than $20 billion to Canada's GDP in 2014, and directly and indirectly employed 288,000 people," says Dr. Catalina Lopez-Correa, Chief Scientific Officer and Vice President, Sector Development at Genome BC. "We have been investing in forest research since 2001 and have funded an earlier phase of Dr. Aitken's genomics and climate-change research because this industry is critical to BC's economy and this work will make a major difference to future forest outcomes." The project was awarded through Genome Canada's 2015 Large-Scale Applied Research Project Competition Natural Resources and the Environment: Sector Challenges -- Genomic Solutions. Funders of this work include Genome Canada, Genome BC, Genome Alberta, Genome Quebec, BC Ministry of Forests, Lands and Natural Resource Operations, the Forest Genetics Council of BC, and Natural Resources Canada. It is also funded by forest companies including West Fraser, CanFor, and the Sinclair Group, partners in the Vernon Seed Orchard Company, as well as Western Forest Products Inc., and TimberWest Forest Corp. About Genome British Columbia: Genome British Columbia leads genomics innovation on Canada's West Coast and facilitates the integration of genomics into society. A recognized catalyst for government and industry, Genome BC invests in research, entrepreneurship and commercialization in life sciences to address challenges in key sectors such as health, forestry, fisheries, aquaculture, agri-food, energy, mining and environment. Genome BC partners with many national and international public and private funding organizations to drive BC's bioeconomy. In addition to research, entrepreneurship and commercialization programs, Genome BC is committed to fostering an understanding and appreciation of the life sciences among teachers, students and the general public. www.genomebc.ca


News Article | February 16, 2017
Site: www.businesswire.com

NEW YORK--(BUSINESS WIRE)--MSCI Inc. (NYSE:MSCI) announced today that Will Robson has joined the firm as Global Head of Real Estate Applied Research. Mr. Robson will be responsible for providing insight into the challenges of institutional investors worldwide whose portfolios include private and publicly traded real estate, and for translating those insights into products and services that aim to deepen investors’ understanding of portfolios and markets. He joins MSCI from Abu Dhabi Investment Authority (ADIA), where he served most recently as a senior research analyst in ADIA’s global real estate research group. Before joining ADIA, Mr. Robson worked as a research economist for M&G Real Estate and, previously, as an economist at Royal Mail Group Plc. “Will’s experience working with owners and managers of real estate in both developed and emerging markets gives him a global perspective on the challenges that investors in this growing asset class confront daily,” said Sebastien Lieblich, MSCI’s Global Head of Real Estate Research. “His insights will help us as we seek to address challenges that range from global asset allocation to lease-level income trends in specific locations. We are pleased to welcome him to MSCI.” Mr. Robson, who is based on London, joins a global team of researchers and specialists that has decades of experience in real estate and real estate-related securities, including regional and global indexes, as well as performance modeling, data metrics and risk analytics. Mr. Robson holds a master’s degree in economics from the University of York and a bachelor’s degree in economics from Newcastle University. For more than 40 years, MSCI’s research-based indexes and analytics have helped the world’s leading investors build and manage better portfolios. Clients rely on our offerings for deeper insights into the drivers of performance and risk in their portfolios, broad asset class coverage and innovative research. Our line of products and services includes indexes, analytical models, data, real estate benchmarks and ESG research. MSCI serves 97 of the top 100 largest money managers, according to the most recent P&I ranking. For more information, visit us at www.msci.com. This document and all of the information contained in it, including without limitation all text, data, graphs, charts (collectively, the “Information”) is the property of MSCI Inc. or its subsidiaries (collectively, “MSCI”), or MSCI’s licensors, direct or indirect suppliers or any third party involved in making or compiling any Information (collectively, with MSCI, the “Information Providers”) and is provided for informational purposes only. The Information may not be modified, reverse-engineered, reproduced or redisseminated in whole or in part without prior written permission from MSCI. The Information may not be used to create derivative works or to verify or correct other data or information. For example (but without limitation), the Information may not be used to create indexes, databases, risk models, analytics, software, or in connection with the issuing, offering, sponsoring, managing or marketing of any securities, portfolios, financial products or other investment vehicles utilizing or based on, linked to, tracking or otherwise derived from the Information or any other MSCI data, information, products or services. The user of the Information assumes the entire risk of any use it may make or permit to be made of the Information. NONE OF THE INFORMATION PROVIDERS MAKES ANY EXPRESS OR IMPLIED WARRANTIES OR REPRESENTATIONS WITH RESPECT TO THE INFORMATION (OR THE RESULTS TO BE OBTAINED BY THE USE THEREOF), AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, EACH INFORMATION PROVIDER EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES (INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF ORIGINALITY, ACCURACY, TIMELINESS, NON-INFRINGEMENT, COMPLETENESS, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE) WITH RESPECT TO ANY OF THE INFORMATION. Without limiting any of the foregoing and to the maximum extent permitted by applicable law, in no event shall any Information Provider have any liability regarding any of the Information for any direct, indirect, special, punitive, consequential (including lost profits) or any other damages even if notified of the possibility of such damages. The foregoing shall not exclude or limit any liability that may not by applicable law be excluded or limited, including without limitation (as applicable), any liability for death or personal injury to the extent that such injury results from the negligence or willful default of itself, its servants, agents or sub-contractors. Information containing any historical information, data or analysis should not be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. Past performance does not guarantee future results. The Information should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. All Information is impersonal and not tailored to the needs of any person, entity or group of persons. None of the Information constitutes an offer to sell (or a solicitation of an offer to buy), any security, financial product or other investment vehicle or any trading strategy. It is not possible to invest directly in an index. Exposure to an asset class or trading strategy or other category represented by an index is only available through third party investable instruments (if any) based on that index. MSCI does not issue, sponsor, endorse, market, offer, review or otherwise express any opinion regarding any fund, ETF, derivative or other security, investment, financial product or trading strategy that is based on, linked to or seeks to provide an investment return related to the performance of any MSCI index (collectively, “Index Linked Investments”). MSCI makes no assurance that any Index Linked Investments will accurately track index performance or provide positive investment returns. MSCI Inc. is not an investment adviser or fiduciary and MSCI makes no representation regarding the advisability of investing in any Index Linked Investments. Index returns do not represent the results of actual trading of investible assets/securities. MSCI maintains and calculates indexes, but does not manage actual assets. Index returns do not reflect payment of any sales charges or fees an investor may pay to purchase the securities underlying the index or Index Linked Investments. The imposition of these fees and charges would cause the performance of an Index Linked Investment to be different than the MSCI index performance. The Information may contain back tested data. Back-tested performance is not actual performance, but is hypothetical. There are frequently material differences between back tested performance results and actual results subsequently achieved by any investment strategy. Constituents of MSCI equity indexes are listed companies, which are included in or excluded from the indexes according to the application of the relevant index methodologies. Accordingly, constituents in MSCI equity indexes may include MSCI Inc., clients of MSCI or suppliers to MSCI. Inclusion of a security within an MSCI index is not a recommendation by MSCI to buy, sell, or hold such security, nor is it considered to be investment advice. Data and information produced by various affiliates of MSCI Inc., including MSCI ESG Research LLC and Barra LLC, may be used in calculating certain MSCI indexes. More information can be found in the relevant index methodologies on www.msci.com. MSCI receives compensation in connection with licensing its indexes to third parties. MSCI Inc.’s revenue includes fees based on assets in Index Linked Investments. Information can be found in MSCI Inc.’s company filings on the Investor Relations section of www.msci.com. MSCI ESG Research LLC is a Registered Investment Adviser under the Investment Advisers Act of 1940 and a subsidiary of MSCI Inc. Except with respect to any applicable products or services from MSCI ESG Research, neither MSCI nor any of its products or services recommends, endorses, approves or otherwise expresses any opinion regarding any issuer, securities, financial products or instruments or trading strategies and MSCI’s products or services are not intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Issuers mentioned or included in any MSCI ESG Research materials may include MSCI Inc., clients of MSCI or suppliers to MSCI, and may also purchase research or other products or services from MSCI ESG Research. MSCI ESG Research materials, including materials utilized in any MSCI ESG Indexes or other products, have not been submitted to, nor received approval from, the United States Securities and Exchange Commission or any other regulatory body. Any use of or access to products, services or information of MSCI requires a license from MSCI. MSCI, Barra, RiskMetrics, IPD, FEA, InvestorForce, and other MSCI brands and product names are the trademarks, service marks, or registered trademarks of MSCI or its subsidiaries in the United States and other jurisdictions. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and Standard & Poor’s. “Global Industry Classification Standard (GICS)” is a service mark of MSCI and Standard & Poor’s.


News Article | February 15, 2017
Site: www.prweb.com

Given the growing demands placed on the electrical, optical and thermal functionality of LEDs, engineers are paying more and more attention to the advancement of new material properties. To this end, the FLINGO project (Functional Inorganic Layers for Next Generation Optical Devices) was established to develop new materials (layers, in particular) and processes to improve the efficiency and durability of LEDs. As the project coordinator, Osram Opto Semiconductors is working with renowned universities, research institutes and companies to maintain and improve market leadership in innovative LED products. The German Federal Ministry for Education and Research is sponsoring the FLINGO project – set to run through January 2020 – as part of the M-ERA.NET EU initiative, an EU-financed network set up to support the coordination of European research projects. In the FLINGO project, researchers will investigate and combine different deposition methods for thin films such as atomic layer deposition, spray pyrolysis and the sol gel process for manufacturing high-quality LED light sources. Under the leadership of Dr. David O’Brien from Osram Opto Semiconductors, the project partners will be working on the entire bandwidth of new component properties – including extended lifetime, smaller electrical layer resistance and improved light extraction. These require new materials and innovative or adapted deposition processes. “The project objectives can only be achieved with the assistance of a broad-based consortium because they call for improvements, new developments and especially expert know-how across the entire value added chain,” explained O’Brien. Interdisciplinary expertise from five project partners The members of the FLINGO project in addition to Osram Opto Semiconductors are: Uninova from the New University of Lisbon; the Finnish thin film technology company Picosun Oy; the Fraunhofer Institute for Silicate Research ISC in Würzburg; and Vilnius University. Fraunhofer ISC provides support with its proficiency in the development of new inorganic layer systems which are to be used as the matrix for sensitive converter materials. Uninova adds its expertise in the manufacture of highly transparent and highly conductive layers which are needed for the p-contact in the LEDs. Picosun Oy is developing atomic layer deposition (ALD) processes and new materials to ensure conformal coating of even heavily structured surfaces. The Institute for Applied Research at Vilnius University provides specialist knowledge in the development and characterization of non-destructive material properties and will analyze the new layers and layer systems developed in the FLINGO project. As an end user of the technologies developed in FLINGO, Osram Opto Semiconductors will ultimately transfer the new thin layers and layer systems to its LEDs to test them for their suitability for the mass market. “The results of the project should lead to highly efficient and durable white light LEDs with possible applications in general lighting for example,” added O’Brien. “Our intention here is to improve our competitiveness and that of European industry in this field.” ABOUT OSRAM OSRAM, based in Munich, is a globally leading lighting manufacturer with a history dating back about 100 years. The product portfolio includes high-tech applications based on semiconductor technology such as infrared or laser lighting. The products are used in highly diverse applications ranging from virtual reality, autonomous driving or mobile phones to smart and connected lighting solutions in buildings and cities. In automotive lighting, the company is the global market and technology leader. Based on continuing operations (excluding Ledvance), OSRAM had around 24,600 employees worldwide at the end of fiscal 2016 (September 30) and generated revenue of almost €3.8 billion in that fiscal year. The company is listed on the stock exchanges in Frankfurt and Munich (ISIN: DE000LED4000; WKN: LED400; trading symbol: OSR). Additional information can be found at http://www.osram.com.


News Article | February 20, 2017
Site: www.futurity.org

When a child suffers a mild head injury, doctors have well-established protocols for determining whether that child should have a computed tomography (CT) scan to assess the damage. Most children with mild traumatic brain injury have normal CT scans—a scenario referred to as a concussion. If a CT scan is abnormal, however, a child’s condition is at higher risk of deteriorating, requiring monitoring in a hospital. But there is little consensus about how closely such children should be monitored. Some children recover well, while others experience a neurological decline and need surgery to relieve brain swelling. Pediatric neurosurgeons have developed a risk scoring system intended to help determine whether a child with mild traumatic brain injury and an abnormal CT scan can be monitored safely in a general hospital ward or requires the increased surveillance of an intensive care unit. “We want to care for these children in the safest way possible and at the same time not place kids unnecessarily in ICUs if they don’t need that level of care,” says senior author David D. Limbrick, professor of neurological surgery and of pediatrics and director of the Division of Pediatric Neurosurgery at Washington University in St. Louis. “We have identified factors that indicate which of these patients are likely to experience neurological decline and require surgery and which are not. This information can help health-care providers decide where to place these children when they are admitted into the hospital.” For the study in JAMA Pediatrics, researchers plumbed data from more than 40,000 children evaluated from 2004 to 2006 at 25 North American hospital emergency departments. The information originally comes from a study conducted by the Pediatric Emergency Care Applied Research Network, which established the standard framework for deciding whether a child with a mild head injury should have a head CT scan. Researchers returned to this data set for guidance on how to handle the subset of children who receive CT scans and are shown to have abnormal findings on the scans. Of the 40,000 children enrolled in the study, 15,000 had CT scans following mild traumatic brain injury. Of these, 839 patients showed abnormalities on the CT scan, such as a brain bleed. These types of injuries are serious enough that some children will experience a neurological decline and need surgery to relieve swelling or pressure on the brain. In the United States, traumatic brain injury leads to almost 600,000 emergency room visits annually. Of new pediatric brain injury cases, more than 90 percent are determined to be mild. About one-third of the 50,000 to 60,000 children hospitalized each year due to head trauma have mild traumatic brain injury. Based on an analysis of the injuries these patients suffered and how they recovered, the investigators developed a risk score ranging from zero to 24 points, called the Children’s Intracranial Injury Decision Aid score. Higher scores indicate the patient is at higher risk of neurological decline and should receive increased monitoring. Lower scores mean a patient is at lower risk of neurological decline. A score of zero indicates the child is at very low risk. The chance that such a child would go on to experience a neurological decline that requires surgery is less than 1.5 percent, according to the analysis. As a general rule, children with scores of less than three points can safely be admitted to a general ward. Patients with higher scores should receive increased surveillance up to and including that provided in an ICU. “There is a lot of variability in how these patients are managed,” says first author Jacob K. Greenberg, a neurosurgery resident. “When we looked back at the data, we saw situations where children were perhaps put in the ICU but didn’t need to be there. And conversely, some patients were placed in a general ward when their risk factors suggested they needed closer monitoring. We are trying to develop this evidence-based tool to help guide and standardize this decision-making process.” The score is determined by four factors that the researchers found most predictive of patient outcomes. One factor is called the Glasgow Coma Scale (GCS), which is used to measure how alert and responsive a patient is after a blow to the head. Fifteen is the highest and best GCS score, meaning the patient can open his or her eyes spontaneously, follow commands to move different body parts and answer questions clearly and appropriately. While the GCS is based on a doctor’s interaction with a patient, the other three factors are determined based on an analysis of a CT scan. The biggest risk factors seen in a CT image are a depressed skull fracture and what is referred to as a midline shift, when the symmetrical structures of the brain are pushed off-center. The final risk factor is an epidural hematoma—a blood clot between the outer layer of the brain’s protective covering and the inside of the skull. Patients with mild traumatic brain injury who show these features on a CT scan and also have a lower GCS score are at high risk of experiencing a neurological decline and, according to the researchers, should be cared for in an ICU. “There are a variety of potential harms associated with sending a patient to an inappropriate location,” Greenberg says. “I think the most important is that if you send a child who needs the ICU into a general hospital ward, you risk missing a potential decline that could have been caught earlier. If the patient experiences new weakness or worsening mental status, for example, the goal is to intervene as quickly as possible to avoid permanent disability or even death. “On the other hand, if you send too many patients to the ICU, there are significant financial costs there, as well as emotional costs for the family,” he says. “Another concern is the limited space available in pediatric ICUs. Having children in the ICU who don’t need to be there is taking beds away from other patients who do need those resources.”


ANN ARBOR, Mich.--(BUSINESS WIRE)--LLamasoft, a global leader in supply chain optimization software and solutions, is proud to announce that three members of the team have been named to Supply and Demand Chain Executive’s list of ‘Pros to Know’ for 2017. Allison Fowler is director of solution design at LLamasoft and holds experience as both a provider and a practitioner, beginning her career at Pepsico. At LLamasoft, Fowler serves as a key link in the sales cycle and holds deep technical expertise of the LLamasoft products. Fowler is also an essential member of the LLamasoft Benefit Benchmark Survey (BBX) research team, which is now in its third year and collects data points from customers after they’ve completed projects to gain a holistic view of the value they derive from supply chain modeling technology. Carlos Valderrama is the vice president of global customer success at LLamasoft. Starting his career at LLamasoft as the managing director of the company’s Latin American operations, Valderrama opened up the market to where it stands today as a key revenue driver. In late 2015, Valderrama moved over to lead the LLamasoft customer success initiative, supporting customers in their efforts to build a three-year roadmap for developing their supply chain design capability and ensures customers are happy with the solutions and the value they drive for their respective organizations. Jim Wilson is the director of product management at LLamasoft and holds 20 years of experience in the supply chain and logistics industry. Wilson is leading a cross-functional team including Product Development, Customer Success and Applied Research to prepare for the company’s move into the supply chain planning space with launch of its new planning platform later this year. This customizable and flexible apps-based approach to supply chain planning will be the first solution of its kind of the market. “I’m proud to have three members of the LLamasoft team recognized in this year’s list of Pros to Know,” said CEO and President of LLamasoft, Don Hicks. “The depth of talent at LLamasoft is vast and this year’s recipients are demonstrative of many of the best qualities of the LLamasoft team, and certainly reflect the variety of areas in which our offerings are strong.” LLamasoft has had leaders named to the annual list every year since 2006, highlighting the benefits of supply chain modeling technology and best practices to large businesses worldwide. LLamasoft supply chain design software helps organizations worldwide design and improve their supply chain operations. LLamasoft solutions enable companies across a wide range of industries to model, optimize and simulate their supply chain network, leading to major improvements in cost, service, sustainability and risk mitigation. Headquartered in Ann Arbor, Michigan, LLamasoft is a leader in supply chain excellence and innovation, advancing technology focused on continuous improvement of enterprise supply chains for the world’s largest organizations.


Heiselberg H.,Applied Research
Physical Review A - Atomic, Molecular, and Optical Physics | Year: 2011

Itinerant ferromagnetism in cold Fermi gases with repulsive interactions is studied applying the Jastrow-Slater approximation generalized to finite polarization and temperature. For two components at zero temperature, a second-order transition is found at akF0.90 compatible with results of quantum-Monte-Carlo (QMC) calculations. Thermodynamic functions and observables, such as the compressibility and spin susceptibility and the resulting fluctuations in number and spin, are calculated. For trapped gases, the resulting cloud radii and kinetic energies are calculated and compared to recent experiments. Spin-polarized systems are recommended for effective separation of large ferromagnetic domains. Collective modes are predicted and tricritical points are calculated for multicomponent systems. © 2011 American Physical Society.

Loading Applied Research collaborators
Loading Applied Research collaborators